Search

Your search keyword '"OVERALL survival"' showing total 5 results
5 results on '"OVERALL survival"'

1. Clinical Updates: KIDNEY CANCER. Updated data show OS benefit with adjuvant pembrolizumab in ccRCC.

Author

CLARKE, HANNAH and HOLLASCH, MEGAN

Subjects
*THERAPEUTIC use of monoclonal antibodies, *RISK assessment, *PLACEBOS, *DEATH, *CANCER relapse, *DRUG side effects, *PATIENT safety, *CLINICAL trials, *TERMINATION of treatment, *NEPHRECTOMY, *RENAL cell carcinoma, *DISEASE relapse, *PROGRESSION-free survival, *TUMOR classification, *OVERALL survival, *PATIENT aftercare, *EVALUATION, *DISEASE risk factors
Abstract

The article discusses updated data as of 2024 which shows that adjuvant pembrolizumab (Keytruda) extended overall survival (OS) in patients with clear cell renal cell carcinoma (ccRCC) at medium or high risk of recurrence. It states that the therapy improved disease-free survival (DFS) and lowered distant and local disease recurrence. Also noted are the occurrences of immune-mediated adverse events (AE) and infusion reactions among patients.

Published
2024

2. From the Co-Editor in Chief: BCG-unresponsive NMIBC: Advancements are moving the needle.

Author

Cookson, Michael S.

Subjects
*NON-muscle invasive bladder cancer, *GENE therapy, *UROLOGY, *BCG vaccines, *IMMUNOTHERAPY, *ANTINEOPLASTIC agents, *DISEASE management, *TREATMENT effectiveness, *SEVERITY of illness index, *IMMUNE checkpoint inhibitors, *OVERALL survival, BLADDER tumors
Abstract

The article highlights advancements in the treatment of Bacillus Calmette-Guerin (BCG)-unresponsive non-muscle-invasive bladder cancer (NMIBC). These include nadofaragene firadenovec intravesical gene therapy, pembrolizumab systemic therapy, TAR-200 drug intravesical delivery system using gemcitabine and gemcitabine plus a PD-L1 inhibitor, combination chemotherapy with gemcitabine and docetaxel, and QUILT-3.032 study on the synergy between immune checkpoint inhibitors and targeted therapies.

Published
2024

3. Prostate cancer treatment deintensification: When less is more.

Author

COOKSON, MICHAEL S.

Subjects
*PROSTATE tumors treatment, *DISEASE progression, *ANTIANDROGENS, *INDIVIDUALIZED medicine, *TREATMENT effectiveness, *RISK assessment, *ADVERSE health care events, *DISEASE management, *PROSTATE tumors, *OVERALL survival
Abstract

In the article, the author discusses updates in the treatment of patients with advanced and metastatic prostate cancer, particularly the clinical trials showing the efficacy of treatment deintensification in the proper clinical context. Other topics include the potential benefits of deintensification like reduction of treatment-related adverse events (TRAE) and the various deintensification methods like radiation therapy with omission of androgen deprivation therapy (ADT).

Published
2023

4. Pembrolizumab/axitinib sustains efficacy in ccRCC at 5-year follow-up.

Author

ROSA, KRISTI

Subjects
*THERAPEUTIC use of antineoplastic agents, *RENAL cell carcinoma, *DRUG efficacy, *PATIENT aftercare, *COMBINATION drug therapy, *COLLEGE teacher attitudes, *TREATMENT effectiveness, *BENZAMIDE, *PROGRESSION-free survival, *OVERALL survival, *THERAPEUTICS
Abstract

The article discusses results from an analysis of the phase three KEYNOTE-426 trial on the efficacy of a combination treatment with pembrolizumab and axitinib, compared with single agent sunitinib, in patients with clear cell renal cell carcinoma (CCRCC). The study evaluated overall survival, progression-free survival, overall response rate, complete response rate, partial response rare, stable disease rate in patients who received pembrolizumab/axitinib and those administered with sunitinib.

Published
2023

5. Hypertension predicts worse outcomes for patients undergoing nephroureterectomy for UTUC.

Author

SAYLOR, BENJAMIN P.

Subjects
*URINARY organ surgery, *ONCOLOGIC surgery, *HYPERTENSION, *CAUSES of death, *NEPHRECTOMY, *URETHRA surgery, *SURGERY, *PATIENTS, *CANCER relapse, *TREATMENT effectiveness, *OVERALL survival, *DISEASE complications, MORTALITY risk factors
Abstract

The article provides information on data presented at the American Urological Association 2023 Annual Meeting in Chicago, Illinois which reported that hypertension is an independent predictor of worsened oncologic and survival outcomes in patients undergoing radical nephroureterectomy for the treatment of upper tract urothelial cancer (UTUC). Topics include rate of high tumor grade observed in patients with hypertension and overall survival of patients with hypertension.

Published
2023

Catalog

Books, media, physical & digital resources
See catalog results